Comparing Tyrosine Phosphorylation Changes after Erlotinib Treatment betweem Drug Sensitive and Drug Resistant Non-small Cell Lung Cancer Lines by Mass Spectrometry
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and survival when treated with the tyrosine kinase inhibitor erlotinib. To elucidate how erlotinib inhibits EGFR, this study included: 1) inhibiting an EGFR mutant cell line to reveal EGFR regulated phosph...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/18883 |